

	Office of Sponsor and Regulatory Oversight	Document #: <b>100</b>
	<b>Quality Policy</b>	Revision #: <b>1</b>
		Effective Date: <b>19JUL2019</b>

## 1. Purpose

To establish and describe the Office of Sponsor and Regulatory Oversight's (OSRO) Quality Program.

## 2. Scope

- 2.1. OSRO in the Center for Cancer Research (CCR), National Cancer Institute (NCI) shall establish and control the policy.
- 2.2. CCR investigators, research team members and other departmental personnel when they are working on studies conducted under a CCR-held Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or Master Files (MF) under OSRO oversight shall follow the policy.
- 2.3. Limitation
  - 2.3.1. CCR personnel are not bound to this policy when working on non-IND or IDE studies and/or no interdepartmental collaboration with OSRO as Sponsor is required.

## 3. Responsibilities

- 3.1. The Center for Cancer Research Management is committed to providing resources to meet the requirements for implementing a Quality Management System (QMS) within OSRO and supporting its continual improvement.
- 3.2. OSRO personnel are responsible for understanding and using the Quality Management System.
- 3.3. OSRO Director is responsible for establishing and maintaining OSRO's QMS.

## 4. References

- 4.1. U.S. Department of Health and Human Services' Guidance for Industry: E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1), dated March 2018
- 4.2. Applicable International Conference on Harmonisation (ICH) Guidelines, [www.ich.org](http://www.ich.org)
- 4.3. Applicable U.S. Code of Federal Regulations (CFR) Title 21 Food and Drugs, [www.ecfr.gov](http://www.ecfr.gov)

## 5. Definitions

Refer to the OSRO Lexicon.

## 6. Policy

- 6.1. OSRO shall establish a QMS to manage quality throughout the entire clinical study process. The OSRO approach to quality will be risk-based. The QMS will help ensure that clinical trials are conducted, and data are generated, recorded, and reported, in compliance with the clinical trial protocol, Good Clinical Practices, Good Manufacturing Practices, Good Laboratory Practices, Good Documentation Practices, and other applicable regulatory requirements.
- 6.2. CCR Clinical Director assigns the responsibility to establish the QMS to the Director, OSRO.

	Office of Sponsor and Regulatory Oversight	Document #: <b>100</b>
	<b>Quality Policy</b>	Revision #: <b>1</b>
		Effective Date: <b>19JUL2019</b>

- 6.3. OSRO shall ensure regulatory compliance of its managed clinical trials by performing the following responsibilities.
  - 6.3.1. Serving as clinical trial Sponsor and meeting all Sponsor obligations.
  - 6.3.2. Participating in the Protocol Development process and providing Sponsor approval for protocols prior to submission to the FDA.
  - 6.3.3. Monitoring clinical trials to verify that the rights and well-being of human subjects are protected; reported trial data are accurate, complete, and verifiable from source documents, and trial conduct complies with the approved protocol or current amendment(s), with Good Clinical Practices, and with applicable regulatory requirements.
  - 6.3.4. Tracking safety and pharmacovigilance by reviewing and approving safety reports; reporting serious adverse events (SAEs) to investigators and if required, to regulatory agencies.
  - 6.3.5. Preparing and submitting IND applications, IDE, MF and other manufacturing information as appropriate, to the FDA. Ensuring that the trial and all documentation is in full compliance with current regulations.
  - 6.3.6. Providing data analytics support to mine clinical databases for information on improving patient care and safety.
- 6.4. This Quality Policy shall be reviewed periodically and updated as necessary.

**7. Change Summary**

Revision Number	Effective Date	Description of Change
1	19JUL2019	New Document